TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03360513

Intervention type: OTHER
Intervention: general group
Description: The sample comprised maxillary and mandibular dental casts of 70 Caucasian Brazilian individuals (28 men and 42 women) with an average age of 16.4 years, all of which had natural normal occlusion with at least four of the six keys to normal occlusion. 14 The first item of the first key was considered essential for sample selection(Angle Class I molar relationship). Another inclusion criterion was that individuals should be at least 15 years of age with no odontogenic abnormalities and all permanent teeth in occlusion.
Study: NCT01641900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: 3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
Study: NCT02310581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Sublingual Spray
Description: Buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
Study: NCT04178213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of ADAPT 3D ALR
Description: The operation is performed through a median sternotomy and with the hemodynamic support of standard cardiopulmonary bypass (CBP). diseased leaflets are excised meticulously. Calcifications at the level of the annulus will be removed just like in any other aortic valve replacement procedure. The annulus will be sized and the appropriate 3D single piece valve will be chosen. The implant technique will consist out of one running suture line at the level of the annulus, followed by fixation of the 3 commissural parts against the aortic wall. Valve competence and function will be assessed visually, and by TEE immediately coming of bypass.
Study: NCT01185041

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Watermelon Extract
Description: 6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Watermelon Extract
Description: 6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
Study: NCT03005912

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional bluetooth telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VoIP acoustic telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VoIP bluetooth telephony
Description: Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
Study: NCT00446290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Capecitabine and Oxaliplatin
Study: NCT00040664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir oral capsules or oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir oral capsules or oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: ritonavir oral capsules or oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir
Description: fosamprenavir oral suspension or tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir
Description: fosamprenavir oral suspension or tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir
Description: fosamprenavir oral suspension or tablet
Study: NCT03049280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery
Description: Transoral robotic surgery for T1 \& T2 oropharyngeal cancers
Study: NCT02421276

Intervention type: OTHER
Group type: OTHER
Intervention: Phlebotomy
Description: White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry

Intervention type: OTHER
Group type: OTHER
Intervention: Phlebotomy
Description: White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
Study: NCT03763591

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Systems Therapy for Refugees Group Intervention
Description: Psychological skills group for youth of refugee and immigrant backgrounds.
Study: NCT02101476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Percocet
Description: 10mg/650mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xartemis
Description: 15mg/650mg
Study: NCT03504150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPHERE
Description: Comprehensive Internet-based CBT program with no human support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PRISM
Description: Brief Internet-based CBT program with no human support
Study: NCT00447642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LX201
Description: LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.~LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded.
Study: NCT01115894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100 mg oral dosage daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 100 mg oral dosage daily for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Behavioral Self-Control Psychotherapy
Description: Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Therapy
Description: Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT03614481

Intervention type: GENETIC
Intervention: Sampling
Description: Sampling

Intervention type: GENETIC
Intervention: Sampling
Description: Sampling
Study: NCT01441908

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 40mg or 80mg dose 28 days for 6 month period
Study: NCT03523793

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Practice Guideline Implementation
Description: The Study team will use several methods from the implementation strategy taxonomy of the Effective Practice and Organization of Care (EPOC) classification system to improve our likelihood for successful neck and low back pain implementation consisting of: 1) educational materials, workshops and outreach visits from trainers; 2) external consultant testimonials; 3) iterative quality improvement processes (including ongoing analysis of clinician feedback to improve process); 4) routine collection of patient reported outcomes to engage discussion among clinician groups and outpatient division leaders) and 5) local organization consensus process (including feedback from key outpatient division stakeholders).
Study: NCT00447642

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
Study: NCT03523793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Considering the stepped wedge design with a 12-week washout phase, clinics will be providing standard physical therapy prior to receiving clinical practice guideline training.
Study: NCT03479177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: The exercise sessions will be based on exercises the participant can confidentially engage in (regular push-ups vs. knee push-ups vs. wall push-ups). The goal will be to engage in three exercise sessions per week. The participants will receive weekly telephone calls during the first month and bi-weekly calls during months 2 and 3. The exercise counselor will also engage in dialogue that will motivate the participant to exercise.
Study: NCT03222934

Intervention type: DEVICE
Intervention: multislice computed tomography
Description: radiological diagnosis of the status and variations in the sphenoid sinus
Study: NCT03768466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brand Name: Targin®
Description: Brand Name: Targin® Generic name: Oxycodone/Naloxone dosage form: Oral
Study: NCT01493882

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 30 mg/d
Description: Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 100 mg/d
Description: Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
Study: NCT03792282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will receive a diet of 1200-1500kcal/d and be instructed to eat only during a window of 8 hours (Finishing the last meal before 4pm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants receive a general lifestyle counseling.
Study: NCT01493882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979 300 mg/d
Description: Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
Study: NCT02199626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Second generation of colon capsule endoscopy (GIVEN IMAGING)
Study: NCT04919850

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saccharomyces boulardii and SOD
Description: A complex of 250 mg of Saccharomyces boulardii and 500 IU SOD to be assumed twice/day for 8 weeks at mealtimes

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo consisting of capsules containing the same excipients except the active compounds, and the same coating
Study: NCT04163237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: PD-1 (programmed death receptor 1), an important immunosuppressive molecule, is an immunoglobulin superfamily and is a membrane protein of 268 amino acid residues. It was originally cloned from apoptotic mouse T cell hybridoma 2B4.11. Immunomodulation targeting PD-1 has important implications for anti-tumor, anti-infective, anti- autoimmune diseases and organ transplant survival. Its ligand PD-L1 can also be used as a target, and the corresponding antibodies can also play the same role. PD-1 and PD-L1 bind to initiate programmed cell death of T cells, allowing tumor cells to gain immune escape.
Study: NCT03541720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DA
Description: 18F-DA is an investigational PET radiotracer
Study: NCT03682666

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotaping
Description: Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Kinesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified Constraint Induced Movement Training
Description: A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: modified Constraint Induced Movement Training
Description: A 2-hour time period would be arranged to constraint patient's unaffected hand by using a bandage by a therapist. During this two hours, patients would not be allowed to use this unaffected to do any activity, so that they will need to use the affected hand. The caregivers would also be educated to provide less help if it is not necessary. This intervention would be executed two hours a day for five days per week, for three weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
Study: NCT02151760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Study: NCT00851383

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN/ENV
Description: This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad35-GRIN
Description: This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
Study: NCT00881712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET positive nodal disease measuring 15 mm or greater
Description: Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET positive nodal disease measuring less than 15 mm
Description: Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
Study: NCT02793505

Intervention type: DRUG
Intervention: metformin
Description: This is not an intervention but an observed exposure.
Study: NCT00881712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Patients considered resectable
Description: Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
Study: NCT03283592

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rank-Heat Plot
Description: provides a visual presentation of treatment hierarchy across multiple outcomes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SUCRA Plot
Description: provides a visual presentation of treatment ranking for a single outcome.
Study: NCT03900351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wii fit protocol of virtual reality games
Description: the Wii fit session by standing on the Wii fit board with bare feet, hands on hips and both eyes open. Pretest on Wii fit was done to make the subject familiar with the board and tasks of weight shift .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular exercise rehabilitation protocol
Description: It will be according to the criterion of Adams et al. (2012).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regular exercise rehabilitation protocol
Description: It will be according to the criterion of Adams et al. (2012).
Study: NCT00258245

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide \[ATO\] days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Description: Thalidomide (Thalomid) - 50 mg/day by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin - 325 mg by mouth (PO) every day
Study: NCT01634971

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Drainage of Pancreatic Duct after pancreatomy
Description: the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
Study: NCT04942691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: training with trampoline. Each session lasted sixty minutes. Organization: a 5 minutes warm-up with breathing and mobility exercises from upper to lower body, central phase with jumping exercises involving the total body and 5 minutes of cool-down phase with total body active stretching exercise.
Study: NCT01689701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hizikia Fusiformis extract
Description: Hizikia Fusiformis extract(1.3g/d)
Study: NCT04163237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.

Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib
Description: Sorafenib tosylate is a novel multi- target anti-tumor drug developed by Bayer Pharmaceuticals, Germany, which acts on both tumor cells and tumor blood vessels. It has a dual anti-tumor effect: it directly inhibits tumor cell proliferation by blocking RAF/MEK/ERK-mediated cell signaling pathways, and also by inhibiting VEGFR and platelet- derived growth factor (PDGF) receptors. Blocking the formation of tumor neovascularization, indirectly inhibiting the growth of tumor cells.
Study: NCT04242212

Intervention type: BEHAVIORAL
Intervention: Misoprostol sourced from clinics
Description: One cohort of women using misoprostol sourced from clinics

Intervention type: BEHAVIORAL
Intervention: Misoprostol sourced from PMVs
Description: One cohort of women using misoprostol sourced from PMVs
Study: NCT05561231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with C blade
Description: Intubation with C blade of CMAC videolaryngoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation with D blade
Description: Intubation with D blade of CMAC videolaryngoscope